HIV/AIDS Statistics for Kenya
Total population in thousands (2007): 37,538*
Number of people living with HIV (2007): 1,500,000 -- 2,000,000*
Adults aged 15 and up living with HIV (2007): 1,400,000-1,800,000*
Women aged 15 and up living with HIV (2007): 800,000-1,100,000*
Women aged 15 to 24 prevalence rate (2007): 4.6 -- 8.4*
Men aged 15 to 24 prevalence rate (2007): 0.8 -- 2.5*
Deaths due to AIDS (2007): 85,000 -- 130,000*
Estimated number of pregnant women living with HIV (2007): 76,000†
Ongoing biomedical HIV prevention research trials in Kenya
Vaccines
Trial: IAVI B003/IPCAVD-004
Phase: I
Start Date: October 2010
Sponsor, funder, developer: IAVI, HVTN,NIAID, Beth Israel Deaconess Medical Center, Ragon Institute of MGH, MIT, Harvard
Total participants: 212
Vaccine(s): Prime: Ad26.EnvA01 Boost: Ad35- ENV
Trial: RV262
Phase: I
Start Date: September 2010
Sponsor, funder, developer: NIAID
Total participants: 92
Vaccine(s): Prime: PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Boost: MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL)
Clade: A, B, C, D, E
Trial: PedVacc001/PedVacc002
Phase: I
Start Date: November 2009
Sponsor, funder, developer: Medical Research Council, EDCTP
Total participants: 48
Vaccine(s): MVA.HIVA
Back to Top ↑
Microbicides
Trial: Safety and acceptability trial of dapivirine gel, conducted using daily monitored adherence in healthy HIV-negative women [IPM 014A]
Phase: I/II
Product Being Tested: Dapivirine gel
Sponsor, funder, developer, collaborator: International Partnership for Microbicides, Kenya Medical Research Institute
Total participants: 320
Countries: Kenya, Malawi, Rwanda, South Africa
Trial sites in Kenya: Kisumu
Results expected: July 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00917904?term=IPM014B&rank=1
Trial: Dapivirine vaginal ring safety [IPM 015]
Phase: I/II
Product Being Tested: Dapivirine vaginal ring
Sponsor, funder, developer, collaborator: International Partnership for Microbicides
Total participants: 280
Countries: South Africa, Kenya, Malawi, Rwanda, Tanzania
Results expected: n/a
For more information: http://www.clinicaltrials.gov/ct2/show/NCT01071174?term=dapivirine+vaginal+ring&rank=1
Back to Top ↑
Pre-Exposure Prophylaxis
Trial: Pre-Exposure Prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples [PartnersPrEP]
Phase: III
Product Being Tested: Daily oral TDF & daily oral TDF/FTC
Sponsor, funder, developer, collaborator: Bill and Melinda Gates Foundation; Moi University - Indiana University; Kenyatta National Hospital/University of Nairobi; CMR, Kemri-UCSF; Partners in Prevention - Thika
Total participants: 4,700
Countries: Kenya, Uganda
Trial sites in Kenya: Eldoret, Nairobi, Kisumu, Thika
Results expected: 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00557245
Back to Top ↑
Partner Treatment
Trial: Evaluation of the effectiveness of two antiretroviral treatment strategies to prevent HIV transmission in HIV-serodiscordant couples [HPTN 052]
Phase: III
Product Being Tested: Highly active antiretroviral therapy for HIV prevention
Sponsor, funder, developer, collaborator:HIV Prevention Trials Network, Gaborone Prevention/Treatment Trials CRS
Total participants: 1,750 couples
Countries: Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, Zimbabwe
Trial sites in Kenya: Kisumu
Results expected: n/a
For more information: http://www.hptn.org/research_studies/hptn052.asp
Trial: Safety and acceptability trial of dapivirine gel, conducted using daily monitored adherence in healthy HIV-negative women [IPM014A/B]
Phase: I/II
Product Being Tested: Dapivirine gel
Sponsor, funder, developer, collaborator: International Partnership for Microbicides, Kenya Medical Research Institute
Total participants: 320
Countries: Kenya, Malawi, Rwanda, South Africa, Tanzania
Trial sites in Kenya: Kisumu
Results expected: July 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00917904?term=IPM014B&rank=1